(TheNewswire)
VANCOUVER, BC – TheNewswire - February 6 , 202 4 - AREV Life Sciences GlobalCorp. (CSE:AREV) (OTC:AREVF) (“AREV” or “the Company” ) AREV Life Sciences is pleased to announcesubstantial corporate development during the recent trading suspensionperiod underscoring our team's dedication to operations and innovationduring this time.
The Company is pleased to report thesuccessful completion of a pivotal transition in our audit andfinancial reporting processes. Our new auditing partners havecompleted an in-depth review of Arev's financials, resulting in thefiling of our annual audit alongside three quarterly reports. Byintegrating and working with our audit partner’s financial processesand reporting, AREV is in full regulatory compliance and foreseesregular reporting in the future as per requirements of the CanadianStock Exchange.
During the trading suspension, Arev hasnot only maintained but accelerated its growth trajectory. In astrategic move designed to enhance our research and productioncapabilities, Arev has relocated its Research & Development(R&D) and Production facilities from Coquitlam to Salt SpringIsland. The transition has already yielded promising outcomes, withthe development of new formulations derived from our proprietaryextracts of cucumaria frondosa, also known as the orange-footed seacucumber. Extract formulations and innovations were focused onvarious advanced wound care applications, reducing inflammation andimmunmodulation as sea cucumber extracts have untapped potential andundiscovered use in these applications.
Building on the momentum of our May 9,2023 announcement, Arev has made forward strides in integratingartificial intelligence (AI) into its operations and optimizingformulas and combination therapies. Specifically, the Company hasharnessed the latest 4.0 Plus functionalities from Open AI, thecreators of Chat GPT, to develop a Custom Naturopathic PharmacologyMachine (NPM). This state-of-the-art AI tool is designed to meetArev's specific research needs, enabling the creation of custom botsidentifying efficacious molecules in approved drugs then match them tosynergistic natural compounds with similar or complimentary mechanismof action to improve the efficacy, decreased toxicity, and reduceddrug resistance of pharmaceuticals. With 21 versatile modes, AREV’sAI technology will revolutionize how the Company approachesformulations and Combination Therapy. Furthermore, using its AItechnology, the company has already identified certain compounds andformulated proprietary compositions, including combination therapieswith its sea cucumber extracts, that may improve pharmaceuticals inmultiple ways and is reviewing patent applications with the guidanceof its US patent attorneys.
The integration of AI into our researchframework marks a significant milestone in our journey towardsdeveloping cutting-edge health solutions. The Company is now in theprocess of demonstrating its ability to innovate new biotechnologyapplications as the company has completed two preclinical in vivostudies and is waiting for the results of its third study. The resultswill be released over the coming weeks.
As we work towards resuming trading,AREV is more poised than ever to embark on the next phase of itsgrowth. We are grateful for the continued support of our investors andthe community, and we look forward to sharing our future successes inthe near term.
For further information, contact MikeWithrow, arevlifesciences@gmail.com 778-896-6536. For more informationvisit www.arevlifesciences.com.
On behalf of the Board,
Michael C. Withrow
CEO & Director
About AREV LifeSciences Global Corp.
AREV Life Sciences Global Corp. strivesfor innovation in the quest for natural compounds and compositions foruse in Combination Therapy to address select global health challengesof our time. With a fully integrated approach, the company specializesin the extraction of compounds for internal and topical application,the identification of advanced combination therapy techniques, and theimplementation of a cutting-edge AI technology platform, theNaturopathic Pharmacology Machine.
Dedicated to producing pharmaceuticalgrade compounds and formulating exclusive therapeutic interventions,AREV leverages its core competency in extraction and separationtechnologies to fuel its pipeline of revolutionary therapeuticproducts. As a member of both BIOTECanada and The BiotechnologyInnovation Organization (BIO), AREV Life Sciences Global Corp. alignswith the highest standards of excellence in biotechnological research,aiming to contribute meaningful solutions to pressing health issueswhile emphasizing sustainability and efficacy.
NEITHER THE CANADIAN SECURITIES EXCHANGENOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPTRESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THISRELEASE.
Neither the Canadian Securities Exchangenor its Regulation Services Provider (as that term is defined inpolicies of the CSE) accepts responsibility for the adequacy oraccuracy of this release. This news release may includeforward-looking statements that are subject to risks anduncertainties. All statements within, other than statements ofhistorical fact, are to be considered forward looking. Although theCompany believes the expectations expressed in such forward lookingstatements are based on reasonable assumptions, such statements arenot guarantees of future performance and actual results ordevelopments may differ materially from those in forward-lookingstatements. Factors that could cause actual results to differmaterially from those in forward-looking statements include marketprices, exploitation and exploration successes, and continuedavailability of capital and financing, and general economic, market orbusiness conditions. There can be no assurances that such statementswill prove accurate and, therefore, readers are advised to rely ontheir own evaluation of such uncertainties. We do not assume anyobligation to update any forward-looking statements except as requiredunder the applicable laws. This press release contains forward-lookingstatements. The use of any of the words "anticipate","continue", "estimate", "expect","may", "will", "project","should", "believe" and similar expressions areintended to identify forward-looking statements. Although theCompany believes that the expectations and assumptions on which theforward-looking statements are based are reasonable, undue relianceshould not be placed on the forward-looking statements because theCompany can give no assurance that they will prove to be correct.Since forward-looking statements address future events and conditions,by their very nature they involve inherent risks and uncertainties.These statements speak only as of the date of this press release.Actual results could differ materially from those currentlyanticipated due to a number of factors and risks various risk factorsdiscussed in the Company’ s Management ’sDiscussion and Analysis under the Company’s profile on www.sedar.com.
Copyright (c) 2024 TheNewswire - All rights reserved.